Active, Not Recruiting
Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab - CA209-567
Updated: 10 January, 2018 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
Inclusion Criteria: - Moderate, severe, life-threatening or fatal encephalitis events occurring in patients treated with nivolumab and reported to the Sponsor Exclusion Criteria: - Encephalitis cases identified through literature reviews and not reported to the Sponsor - Encephalitis cases identified from company-sponsored observational studies with secondary data collection - Spontaneous reports not submitted directly to the Sponsor Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
